Welcome to our dedicated page for Regeneron Pharmaceuticals news (Ticker: REGN), a resource for investors and traders seeking the latest updates and insights on Regeneron Pharmaceuticals stock.
Regeneron Pharmaceuticals Inc. (symbol: REGN) is a prominent American biotechnology company headquartered in Westchester County, New York, since its founding in 1988. The core mission of Regeneron is to discover, develop, and commercialize innovative products targeting a range of serious medical conditions. With a diverse portfolio, Regeneron focuses on therapies for eye diseases, cardiovascular conditions, cancer, and inflammatory disorders.
Among its marketed products, Eylea stands out as a treatment for wet age-related macular degeneration and other eye diseases. Praluent is designed to lower LDL cholesterol levels, while Dupixent addresses multiple immunological conditions. In the oncology sector, Libtayo is a key therapy, and Kevzara targets rheumatoid arthritis.
The company is also heavily invested in the development of monoclonal and bispecific antibodies, often in collaboration with Sanofi and other partners. These initiatives include cutting-edge technologies such as RNA interference (RNAi) with Alnylam and CRISPR-based gene editing with Intellia.
Regeneron's recent progress includes significant advancements in its clinical-stage pipeline, which comprises over 35 product candidates. The company's financial health remains robust, supported by strong revenue streams from collaboration with Sanofi and a strategic $3.0 billion share repurchase program authorized by the board.
Latest updates highlight the company's ongoing efforts in gene therapy, particularly in treating genetic deafness and solid tumors. Regeneron's commitment to pioneering genetic medicine and leveraging data insights from the Regeneron Genetics Center® positions it as a leader in the biopharmaceutical industry.
For more information, visit Regeneron Pharmaceuticals.
News
Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. announces the acceptance for review of the Marketing Authorization Application for linvoseltamab by the European Medicines Agency. The application is for the treatment of adult patients with relapsed/refractory multiple myeloma who have progressed after at least three prior therapies. The drug is an investigational bispecific antibody designed to facilitate T-cell activation and cancer-cell killing. The MAA is supported by data from a Phase 1/2 pivotal trial and a Biologics License Application was also submitted to the FDA. Multiple trials are planned or underway for linvoseltamab in different stages of multiple myeloma. MM is characterized by the proliferation of cancerous plasma cells and is not curable despite treatment advances.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.32%
Tags
-
Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. has announced the formation of Regeneron Cell Medicines based on an agreement with 2seventy bio, Inc. to acquire full development and commercialization rights to its pipeline of investigational novel immune cell therapies. The company will pay an upfront payment of $5 million and a single milestone payment from Regeneron to 2seventy bio for the first major market approval of the first approved product. Regeneron will also pay 2seventy bio a low single-digit percent royalty on revenues generated by the products. The transaction is expected to close in the first half of 2024 subject to certain closing conditions including SEC-filings required by 2seventy bio and landlord consent of the sublease agreements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.41%
Tags
-
Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. and Sanofi have announced the FDA approval of Dupixent for the treatment of pediatric patients aged 1 to 11 years with eosinophilic esophagitis (EoE). The approval expands the initial FDA approval for EoE in patients aged 12 years and older. The Phase 3 EoE KIDS trial showed that a greater proportion of children taking Dupixent achieved histological remission compared to placebo. The safety profile of Dupixent in children was generally similar to that observed in adult and pediatric patients aged 12 years and older.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.07%
Tags
Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. and Society for Science announce the top 40 finalists in the 2024 Regeneron Science Talent Search, showcasing exceptional young leaders in science and math. The finalists' research projects cover a wide range of topics, from brain disorders and suicide risk to local environment studies. The finalists will compete for more than $1.8 million in awards, with a top prize of $250,000. The competition received the largest pool of applicants since the 1960s, highlighting the increasing importance of scientific exploration and outreach programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.66%
Tags
-
Rhea-AI Summary
Regeneron Pharmaceuticals and Sanofi announced that the FDA has updated the label for Dupixent in atopic dermatitis, adding efficacy and safety data for patients aged 12 years and older with uncontrolled moderate-to-severe hand and/or foot involvement. The Phase 3 trial showed significant improvement in skin clarity and itch reduction for patients treated with Dupixent compared to placebo. The label update is based on data from the Phase 3 LIBERTY-AD-HAFT trial, with patients treated with Dupixent experiencing a 40% achievement of clear or almost clear skin on hands and feet compared to 17% with placebo, as well as a 52% reduction in itch compared to 14% with placebo. The safety profile of Dupixent remains consistent with known data, with common adverse events including injection site reactions, conjunctivitis, and others.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.44%
Tags
-
Rhea-AI Summary
Medison Pharma (Medison) (NASDAQ: REGN) has announced an exclusive multi-national agreement with Regeneron Ireland DAC, a subsidiary of Regeneron Pharmaceuticals, to commercialize Libtayo (cemiplimab) in select European markets and additional markets worldwide. Libtayo is a leading PD-1 inhibitor approved for the treatment of certain patients with cutaneous squamous cell carcinoma, advanced basal cell carcinoma, advanced non-small cell lung cancer, and advanced cervical cancer in more than two dozen countries. The agreement aims to continue patient access to this important therapy and facilitate a seamless transition of commercialization activities to Medison during the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.13%
Tags
Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will report its Q4 and full year 2023 financial and operating results on February 2, 2024. The conference call and webcast will be held at 8:30 AM Eastern Time on the same day. Participants can access the live webcast on the company's website or register in advance for the telephone conference call. A replay and transcript will be available on the website for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.13%
Tags
-
Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024. The presentation is scheduled for 2:15 p.m. Pacific Time (5:15 p.m. Eastern Time) and may be accessed from the 'Investors & Media' page of Regeneron's website. A replay and transcript of the webcast will be archived on the Company's website for at least 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.29%
Tags
-
Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has been included on the Dow Jones Sustainability World Index (DJSI World) for the fifth consecutive year, alongside its fourth consecutive inclusion on the Dow Jones Sustainability North America Index (DJSI North America). Regeneron's dedication to sustainability is reflected in its consistent rankings, acknowledging the top 10 percent of the world's most sustainable companies in each industry. Regeneron stands proud as one of only five biotechnology firms globally to make the list, ranking among the top 2 percent. The company's improvement areas in this year’s assessment were climate strategy, labor practice indicators, and tax strategy. Regeneron's commitment to corporate responsibility is further highlighted by its impressive performance across various top ESG ratings and rankings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.99%
Tags
Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) presented positive data for odronextamab in patients with relapsed/refractory follicular lymphoma (FL) from a pivotal Phase 2 trial (ELM-2) at the 65th American Society of Hematology (ASH) Annual Meeting. The data demonstrated an 80% objective response rate and a 73% complete response (CR), with a 23-month median duration of response and 24-month median duration of CR. Odronextamab is an investigational CD20xCD3 bispecific antibody designed to bridge CD20 on cancer cells with CD3-expressing T cells to facilitate local T-cell activation and cancer-cell killing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.99%
Tags
FAQ
What is the current stock price of Regeneron Pharmaceuticals (REGN)?
The current stock price of Regeneron Pharmaceuticals (REGN) is $701.85 as of December 20, 2024.
What is the market cap of Regeneron Pharmaceuticals (REGN)?
The market cap of Regeneron Pharmaceuticals (REGN) is approximately 77.4B.
What types of diseases does Regeneron Pharmaceuticals focus on?
Regeneron focuses on eye diseases, cardiovascular conditions, cancer, and inflammatory disorders.
What are some of Regeneron's key products?
Key products include Eylea for eye diseases, Praluent for lowering LDL cholesterol, Dupixent for immunology, Libtayo for oncology, and Kevzara for rheumatoid arthritis.
Who are some of Regeneron's notable collaborators?
Regeneron collaborates with Sanofi, Alnylam, and Intellia on various projects, including monoclonal and bispecific antibodies, RNAi, and CRISPR-based gene editing.
What recent financial steps has Regeneron taken?
Regeneron has initiated a $3.0 billion share repurchase program and reported strong financial performance in the first quarter of 2024.
How does Regeneron leverage genetic medicine?
Regeneron utilizes data-powered insights from the Regeneron Genetics Center® and employs proprietary technologies like VelociSuite® to advance drug development.
What is the significance of Eylea in Regeneron's product portfolio?
Eylea is a crucial product for treating wet age-related macular degeneration and other eye diseases, contributing significantly to Regeneron's revenue.
What advancements has Regeneron made in gene therapy?
Regeneron is progressing in gene therapy for genetic deafness and solid tumors, showcasing promising early results in clinical trials.
What is Dupixent used for?
Dupixent is used in treating various immunological conditions and has shown significant growth since its launch, treating over 850,000 patients.
What technologies does Regeneron use for drug development?
Regeneron uses proprietary technologies such as VelociSuite®, which includes platforms for producing optimized human antibodies and bispecific antibodies.
How does Regeneron contribute to scientific discovery?
Regeneron pushes the boundaries of scientific discovery with pioneering genetic medicine platforms and data insights, aiming to develop transformative therapies.
Regeneron Pharmaceuticals Inc
Nasdaq:REGN
REGN Rankings
REGN Stock Data
77.39B
106.22M
1.56%
90.64%
1.63%
Biotechnology
Pharmaceutical Preparations
United States of America
TARRYTOWN